TickerTalks
Browse all tickers →
TickerTalks›$MGNX
MGMGNX

MacroGenics, Inc.

$MGNX·$257M·Biotechnology·Healthcare
$4.13+1.2%YTD+142.2%1Y+142.9%
Mentions · last 7 days
2026-08-20: 4 posts2026-08-21: 0 posts2026-08-22: 0 posts150%
Price updated 2d ago·X counts updated 8d ago
MGMGNX
$MGNXMacroGenics, Inc.
$4.13+1.23%15 posts0%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Today's AI verdict on what's driving $MGNX, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Comeback attemptAcceleratingAI verdict · as of 2026-08-20

The move is getting stronger, with heavier trading behind it.

Small-cap bispecific-antibody biotech trading below cash with Gilead just exercising a partnership option — the setup has real optionality.

MacroGenics is a small-cap clinical-stage biotech developing bispecific antibodies and antibody-drug conjugates (ADCs), primarily for oncology. The company has spent the last two years restructuring after clinical setbacks and is now trading at a market cap below its cash balance — a set of circumstances where the pipeline optionality is essentially free.

  • The valuation-vs-cash discount is the anchor: $258M market cap versus $327M in pro-forma cash — this is a rare setup where the equity is priced below liquidation value, and every dollar of new milestone income is pure upside on the discount.
  • The Gilead milestone is the fundamental signal: Gilead exercised its option to license a second MacroGenics preclinical bispecific program on Aug 18, triggering a $10M milestone with MGNX eligible for up to $1.6B in additional milestones — an active-partnership signal that platform validation is ongoing.
  • The pipeline delivers real catalysts: two ADC readouts in H2 2026, plus one undisclosed ADC entering the clinic in Q3 — the risk is B7H3 (competitive space with Merck and Bristol) and the non-Topo1 payload diversification story is the actual bull thesis that supports a higher multiple.

Trajectory is accelerating at 76% of the 52-week range with the tape pricing in the platform validation; the Nov 11 Q3 print needs to keep the pipeline milestones intact and show cash-runway extension — a soft ADC readout or a partner-program discontinuation drops this back near the cash floor around $2-2.50.

Agrees with X sentimentX's read on the market-cap vs cash setup ($258M vs $327M pro-forma), the Gilead $10M milestone, and the H2 ADC readouts is on the fundamentals — this is a real cash-anchored biotech with meaningful platform validation optionality. The non-Topo1 diversification callout is the thoughtful bull piece.

What to watch: Nov 11 Q3 earnings plus H2 ADC readouts — Gilead partnership progression combined with clean ADC data validates the platform; a soft ADC readout or a partner-program discontinuation drops the stock back near the $2-2.50 cash floor.

On the calendar: 2026-11-11 — Q3 2026 earnings

trades below cashpartnership active

X sentiment

What the X crowd is saying right now — descriptive, summarised from the day’s posts.

Bullish sentiment5 posts analyzed · as of 2026-08-18

Chatter is bullish on MacroGenics. Gilead exercised its option to license a second MGNX preclinical bispecific program triggering a $10M milestone payment — MGNX remains eligible for up to ~$1.6B in additional development/regulatory/commercial milestones. Bulls frame MGNX at ~$258M market cap versus ~$327M in pro-forma cash, two ADC readouts in the back half (with B7H3 acknowledged as crowded), and one undisclosed ADC entering the clinic in 3Q. Non-Topo1 payload ADC diversification is called out as strategically crucial.

Read the AI verdict + X sentiment for $MGNX

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Develops bispecific and Fc-optimized antibody cancer therapies; lead program vobramitamab duocarmazine targets solid tumors.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $MGNX.

Biotechnology · Healthcare

No material change from last week — ADA conference oral formulation competition is bifurcating biotech multiples between GLP-1 platform holders and precision oncology innovators.

What this means for $MGNX

Neutral — Develops bispecific and Fc-optimized antibody cancer therapies; lead program vobramitamab duocarmazine targets solid tumors; limited read-through from biotechnology macro dynamics to this specific revenue mix.

Top industry ETF

$IBBiShares Biotechnology ETF
+12.1%YTD
+51.2%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-3.5How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-49.6%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
-40.5%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-28.8%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
1.6Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-148%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
69.9%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
1.7Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 13, 2026$0.31$-0.08+498.2%
Q1 2026May 13, 2026$-0.58$-0.57-1.8%
Q4 2025Mar 9, 2026$-0.22$-0.42+47.6%
Q3 2025Nov 12, 2025$0.27$-0.48+156.3%
Next earningsWed, Nov 11·consensus EPS $-0.29

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$20.8M+57.5%46.0%-161%$-0.58$-36.2M
Q4 FY25$41.2M+132.5%71.3%-29.3%$-0.22$42.8M
Q3 FY25$72.8M-34.2%81.6%25.6%$0.27$-30.6M
Q2 FY25$22.2M+106.0%51.4%-165%$-0.57$-47.7M

Forward consensus

5-year forecast · up to 4 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$136.3M$102.6M – $170.0M-$1.23-$1.96 – -$0.463
FY27$88.3M$68.4M – $108.1M-$1.23-$1.59 – -$0.874
FY28$172.5M$76.7M – $278.8M-$1.29-$2.19 – -$0.643
FY29$226.4M$133.1M – $319.3M-$0.86-$1.33 – -$0.402
FY30$303.7M$178.5M – $428.3M-$0.27-$0.41 – -$0.121

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.9×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.75%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-2.5%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+39.7%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatMid float · 55.9M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today1.0% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β1.225-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellAug 19Peters Jeffrey StuartSenior VP, GC, and Secretary31.1K sh$129K
+ 19 other (10 exempts · 9 awards) in window

See when $MGNX insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KOfficer or director changeJul 88-K — Item 5.02: Officer or director change
AI summary

MacroGenics announced that director Karen Ferrante, M.D., has resigned from the Board of Directors effective September 1, 2026, citing personal reasons. Her departure was not due to any disagreement with management or the board on matters of company operations, policies, or practices. The company will evaluate whether to replace her seat, though no immediate plans for a new director appointment were disclosed in this filing.

8-KAcquisition completedJul 78-K — Item 2.01: Acquisition completed · Item 7.01: Press release / Reg FD
AI summary

MacroGenics, Inc. completed the sale of its GMP manufacturing and CDMO business to Bora Pharmaceuticals Co., Ltd. (Taiwan) and Bora Biologics USA, LLC on June 30, 2026, pursuant to an Asset Purchase Agreement signed May 11, 2026. The purchase price was $122.5 million before transaction fees and subject to customary post-closing adjustments. Bora assumed responsibility for the CDMO operations at the Rockville, Maryland facility and the Frederick, Maryland warehouse. This is a strategic asset divestiture that enables MacroGenics to focus on its drug pipeline while generating $122.5 million in proceeds.

8-KShareholder voteMay 208-K — Item 5.07: Shareholder vote
AI summary

MacroGenics, Inc. (MGNX) filed an 8-K on May 19, 2026 disclosing annual shareholder meeting vote results (Item 5.07). MacroGenics is a Rockville, Maryland-based clinical-stage biopharmaceutical company listed on Nasdaq. Annual meeting results are routine governance disclosures.

8-KMaterial agreementMay 128-K — Item 1.01: Material agreement · Item 7.01: Press release / Reg FD
AI summary

MacroGenics Inc. (MGNX) filed an 8-K covering two items: a material definitive agreement (Item 1.01) and a Regulation FD disclosure (Item 7.01). The company entered into a new collaboration or licensing arrangement and simultaneously disclosed related information to ensure fair public access. The agreement may involve milestone payments, royalties, or co-development rights with a strategic partner. Full agreement details and any investor presentation materials are filed as exhibits.

8-KMaterial agreementMay 48-K — Item 1.01: Material agreement · Item 8.01: Other event
AI summary

MacroGenics Inc. (MGNX) filed an 8-K disclosing a new material definitive agreement (Item 1.01) alongside other material events (Item 8.01). The clinical-stage biopharmaceutical company entered into a collaboration, licensing, or supply agreement with strategic or financial terms material to the business. The Item 8.01 may cover related announcements or developments tied to the agreement. Full agreement terms are included as exhibits to the filing.

+ 20 other (9 13Gs · 3 earnings 8-Ks · 3 proxys · 2 10-Qs) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Bank of America Corp DE Buys 564,094 Shares of MacroGenics, Inc. $MGNXdefenseworld.net·5d agoIs MacroGenics (MGNX) Stock Outpacing Its Medical Peers This Year?zacks.com·10d agoGilead Sciences Has Quietly Become One of the Most Underrated Turnaround Stories in Healthcare. Here's Why Wall Street Is Excited.fool.com·13d agoMacroGenics (MGNX) Reports Q2 Loss, Lags Revenue Estimateszacks.com·17d agoMacroGenics Reports Second Quarter 2026 Financial Results, Streamlined Operating Model and Strengthened Financial Positionglobenewswire.com·17d ago

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$MRNA$ALT$AURA$IOVA$NWBO$SLS$AMLX$ABCL
Voices on X · last 7 days

No standout posts about $MGNX on X in the last 7 days.

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport